Keapstone Therapeutics Company
Developing a novel series of small molecule activators of the Nrf2-ARE pathway for neuroprotection in Parkinson’s and amyotrophic lateral sclerosis (ALS).
Technology:
AgeTech Companies
Industry:
Healthcare
Headquarters:
United Kingdom
Founded Date:
2017
Employees Number:
1-10
Funding Status:
N/A
Register and Claim Ownership